CN103893174B - A kind of nasal spray for the treatment of of allergic rhinitis - Google Patents

A kind of nasal spray for the treatment of of allergic rhinitis Download PDF

Info

Publication number
CN103893174B
CN103893174B CN201310749348.6A CN201310749348A CN103893174B CN 103893174 B CN103893174 B CN 103893174B CN 201310749348 A CN201310749348 A CN 201310749348A CN 103893174 B CN103893174 B CN 103893174B
Authority
CN
China
Prior art keywords
nasal
allergic rhinitis
treatment
quick
nasal spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310749348.6A
Other languages
Chinese (zh)
Other versions
CN103893174A (en
Inventor
徐宜铁
林航
尹睿
梁霞
李本超
杨金岭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANDONG TIANSHUN PHARMACEUTICAL Co Ltd
Original Assignee
SHANDONG TIANSHUN PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANDONG TIANSHUN PHARMACEUTICAL Co Ltd filed Critical SHANDONG TIANSHUN PHARMACEUTICAL Co Ltd
Priority to CN201310749348.6A priority Critical patent/CN103893174B/en
Publication of CN103893174A publication Critical patent/CN103893174A/en
Application granted granted Critical
Publication of CN103893174B publication Critical patent/CN103893174B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a kind of nasal spray for the treatment of of allergic rhinitis, comprise: sodium cromoglicate, naphcon and chlorphenamine maleate, and be selected from the pharmaceutically acceptable excipient such as buffer agent, osmotic pressure regulator, absorption enhancer, PH regulator.In said preparation, active component absorbs and quick acting rapidly by nasal membrane, has bioavailability high, and compliance is good, the advantage such as to carry and easy to use.

Description

A kind of nasal spray for the treatment of of allergic rhinitis
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of of allergic rhinitis, be specifically related to a kind of nasal spray for the treatment of of allergic rhinitis, belong to field of medicaments.
Background technology
On current market, rhinitis is common frdquently encountered disease, and wherein allergic rhinitis is more common.Allergic rhinitis is allergic rhinitis again, is that systemic anaphylaxis occurs in nasal membrane local symptom, all many factors such as its cause of disease cold wind mostly be in environment is attacked, dust, pollen, animal wool, food (as fish, shrimp) and medicine.The time former because of contact allergy is different from patient's body reaction, is divided into catarrhus perennialis and seasonal allergic rhinitis clinically.The former can occur at any time; Latter betides allergen season, as spring, polliniferous time in autumn.During seizure of disease, often produce nasal obstruction, rhinorrhea, hyposmia, the symptom such as ambiguous of speaking, these symptoms often can affect normal rest and sleep, hinder the health of people and normal work, also can affect suckling during infant rhinostegnosis.Treat these nose diseasess, topical treatment is a kind of good route of administration.Nasal cavity topical is rapid-action, effective, can reduce again the side effect that medicine brings to whole body, its objective is that to make nasal cavity unobstructed, is conducive to the drain of the many secretions of intranasal, recovers the normal function of nose.
Sodium cromoglicate is by the anti-allergic drug of Fisons company in exploitation listing in 1969.It is anaphylaxis medium sustained-release agent, can stablize the cell membrane of mastocyte, stops mast cell degranulation, suppresses the release of the anaphylaxis media such as histamine, 5-hydroxy tryptamine, slow reacting substance, prevents anaphylaxis medium to the untoward reaction of tissue.Good preventive and therapeutic action is had to anaphylactic type, delayed hypersensitivity.Naphcon is adrenomimetic, has vasoconstrictive effect, the effect of the nasal obstruction that nasal mucosa vessels can be made to shrink, have hemostasis, alleviate hyperemia, alleviate.Chlorphenamine maleate is H1 receptor antagonist.Clinically for various anaphylactic reaction.
Disclose the pharmaceutical composition for improvement allergic rhinitis containing sodium cromoglicate, naphcon and chlorphenamine maleate three kinds of active component in Chinese patent literature 94103562.x, and also disclose topical formulations as nasal drop.But because excipient used in nasal drop limit, its therapeutic effect is also not obvious, but also causes the serious side effects such as nasal cavity blood capillary atrophy.
Therefore, provide one to have low toxic and side effects, the pharmaceutical preparation of the treatment of allergic rhinitis of instant effect become Present clinical in the urgent need to.
Usually use phosphate buffer can promote that nasal mucosa is to the absorption of medicine in nasal spray of the prior art, phosphate buffer is made up of sodium dihydrogen phosphate and sodium hydrogen phosphate and forms buffer system; Wherein sodium dihydrogen phosphate acidity is stronger.If the pH value in preparation is too high, unnecessary alkali will be combined with acid phosphoric acid sodium dihydrogen and generate sodium hydrogen phosphate, otherwise, will react with sodium hydrogen phosphate during peracid and produce sodium dihydrogen phosphate.But the acidity effect of phosphate buffer is unfavorable for the recovery of nasal membrane.
Innovative point of the present invention is, adopts the combination of specific absorption enhancer and osmotic pressure regulator instead of original buffer system, not only ensure that pH value, and is realizing, on sorbefacient basis, overcoming original side effect.
In preferred technical scheme, the combination of Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester and mannitol is adopted to instead of the combination of original sodium dihydrogen phosphate and sodium hydrogen phosphate composition formation buffer system.The combination that inventor is surprised to find Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester and mannitol not only overcomes the side effect of original buffer system, also enhances the active function of " sodium cromoglicate, naphcon, chlorphenamine maleate "; More against expectation, the side effect of nasal cavity blood capillary atrophy is reduced.
In the preferred technical scheme of the present invention, 1000 those quick nasal sprays of Zhi Segan naphthalene first comprise following composition:
In the preferred technical scheme of the present invention, 1000 those quick nasal sprays of Zhi Segan naphthalene first comprise following composition:
PH value is 5.5-6.5.
Spray of the present invention, aims at nasal cavity in use, presses sprayer unit, sucks, and each sprays about 0.5ml, can three times on the one during treatment, each 1-3 spray.
Summary of the invention
An object of the present invention, provides one to have low toxic and side effects, the pharmaceutical preparation of the treatment of allergic rhinitis of instant effect.
An object of the present invention, provides a kind of nasal cavity administrated preparation reducing the side effect of sodium cromoglicate, naphcon and chlorphenamine maleate.
The spray preparation that to be a kind of pressure by manual pump disengage content with the form such as vaporific.The invention provides one has easy to use, easily absorbs, and drug effect is fast, and compliance is good, alleviates the spray of side effect simultaneously.
An object of the present invention, that quick nasal spray of a kind of color Gan Naijia is provided, comprise: sodium cromoglicate, naphcon and chlorphenamine maleate, and be selected from the pharmaceutically acceptable excipient such as buffer agent, osmotic pressure regulator, absorption enhancer, pH adjusting agent.
Nasal mist of the present invention, buffer agent used is selected from phosphate, citrate, carbonate, acetate, but is not limited thereto.
Nasal mist of the present invention, osmotic pressure regulator used is selected from sodium chloride, glucose, mannitol, sorbitol, lactose, but is not limited thereto.
Nasal mist of the present invention; absorption enhancer used is selected from cyclodextrin and derivant thereof, sodium ethylene diamine tetracetate, sodium taurocholate, NaTDC, tween, propylene glycol, polyoxyethylene-5-octyl ether, Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester (Solutol HS-15), caprylate, laurate, but is not limited thereto.
In the preferred technical scheme of the present invention, 1000 those quick nasal sprays of Zhi Segan naphthalene first comprise following composition:
Detailed description of the invention
Following examples further illustrate of the present invention, but never limit the scope of the present invention.Elaborate the present invention further referring to embodiment, but it will be appreciated by those skilled in the art that the present invention is not limited to the preparation method of these embodiments and use.And those skilled in the art can carry out equivalent replacement, combination, improvement to the present invention according to description of the invention or modify, but these all will comprise within the scope of the invention.
That quick nasal spray of embodiment 1 color Gan Naijia
Prescription: 1000
Preparation technology: get the sodium cromoglicate of recipe quantity, naphcon, chlorphenamine maleate, Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester, sorbitol in appropriate container, add purified water, stir at normal temperatures, after above-mentioned material dissolution, add purified water to full dose, filter with the microporous filter membrane of 0.22 μm, that quick solution of Dry Sack Gan Naijia, pH value is 6.4, is sub-packed in qualified spray bottle keeping away under bacterium condition, inspection, packaging.
That quick nasal spray of embodiment 2 color Gan Naijia
Prescription: 1000
Preparation technology: get the sodium cromoglicate of recipe quantity, naphcon, chlorphenamine maleate, Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester in appropriate container, add purified water, stir at normal temperatures, after above-mentioned material dissolution, then add sorbitol stirring, finally add purified water to full dose, filter with the microporous filter membrane of 0.22 μm, that quick solution of Dry Sack Gan Naijia, pH value is 5.7, be sub-packed in qualified spray bottle keeping away under bacterium condition, inspection, packaging.
That quick nasal spray of embodiment 3 color Gan Naijia
Prescription: 1000
Preparation technology: get the sodium cromoglicate of recipe quantity, naphcon, chlorphenamine maleate, Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester, sorbitol in appropriate container, add purified water, stir at normal temperatures, after above-mentioned material dissolution, add purified water to full dose, filter with the microporous filter membrane of 0.22 μm, that quick solution of Dry Sack Gan Naijia, pH value is 5.6, is sub-packed in qualified spray bottle keeping away under bacterium condition, inspection, packaging.
The stability test of that quick nasal spray of embodiment 4 color Gan Naijia
The present invention has also carried out study on the stability to the most preferred medicinal liquid of the present invention, and result is as follows:
(1) under this preparation (embodiment 3) being placed in respectively 3000 lux illumination, 92.5%RH (25 DEG C), the condition of 60 DEG C, respectively at sampling in 0,5,10 day, investigate the change of outward appearance, pH value, clarity of solution and color, related substance and content, result shows this preparation and stablizes under these conditions.(2) Acceleration study, by this preparation (embodiment 1) as containing in the exsiccator of saturated sodium-chloride water solution, exsiccator is placed in the calorstat of 40 ± 1 DEG C, respectively at sampling in 0,1,2,3,4,6 month, observe outward appearance, pH value, clarity of solution and color, measure related substance and content.Result shows, this preparation 40 DEG C, under the condition of relative humidity 75%, through 6 months, basically identical with the analysis result of batch sample before the outward appearance of preparation, pH value, related substances and assay and experiment, this preparation stabilization is described.(3) room temperature keeps sample, this preparation being protected (embodiment 2) is stored in after room temperature places a period of time, and the analytical data of the same batch sample before sampling and experiment contrasts, and result shows, this preparation keeps sample 18 months in greenhouse, and its outward appearance, pH value, related substances and assay result are basically identical.Above-mentioned experimental result shows that this preparation stability is good.
The pharmacodynamics test of that quick nasal spray of embodiment 5 color Gan Naijia
Screened Allergic Rhinitis 60 example meeting allergic rhinitis diagnostic criteria, be pressed into group successively random assortment to test group or positive controls, wherein test group 30 example, positive controls 30 example, test group completes 29 examples, and matched group completes 28 examples.The test group application embodiment of the present invention 3 preparation is given and treatment, and concrete grammar is: sooner or later respectively once, and each 2 sprays of every side nasal cavity, the course for the treatment of is one week.Matched group gives to adopt the aerosol therapy that in Chinese patent literature 94103562.x, embodiment 1 composition is made, and concrete grammar is sooner or later respectively once, and each 2 sprays of every side nasal cavity, the course for the treatment of is one week.Terminate to carry out S&S score to experimenter afterwards with treatment respectively at before treatment according to China's allergic rhinitis standards of grading.Score standard is as follows: symptom point system is in table 1.Table 1
Note: * 1 continuous sneeze number; △ blowing the nose every day number of times
Sign score standard: at the bottom of concha nasalis inferior and nose, nasal septum near, can not see concha nasalis or middle nasal concha mucosa Polypoid changes, polyp formation, be recorded as 3 points; Concha nasalis inferior and nasal septum (or at the bottom of nose) still have small gap near at the bottom of, concha nasalis inferior and nose between (or nasal septum), are recorded as 2 points; Concha nasalis mild swelling, nasal septum, middle nasal concha are still visible, are recorded as 1 point
Before after calculating medication as follows, comprehensive therapeutic effect improves percentage rate (before treatment the rear total score of total score-treatment)/treatment, total score × 100% evaluates the curative effect of persistence allergic rhinitis.Result: test group and the recent effective percentage of matched group are respectively 96.5%, 73.5%, and treatment group curative effect is better than matched group.The present invention significantly can improve the symptom such as nasal obstruction, sneeze, rhinocnesmus of allergic rhinitis, has good efficacy to allergic rhinitis.Meanwhile, after drug withdrawal 1 week and 1 month, test group had not found the symptom of nasal cavity blood capillary atrophy; And matched group has 4 examples after 1 week, after 1 month, there is the symptom of 20 routine nasal cavity blood capillary atrophys.

Claims (2)

1. that quick nasal spray of color Gan Naijia, is characterized in that 1000 those quick nasal sprays of Zhi Segan naphthalene first comprise following composition:
sodium cromoglicate 100.0g naphcon 2.5g chlorphenamine maleate 25.0g polyethyleneglycol-12-hydroxy stearin 50g sorbitol 30g purified water add to 10000ml.
2. the application of that quick nasal spray of color Gan Naijia according to claim 1 in the medicine of preparation treatment of allergic rhinitis.
CN201310749348.6A 2013-12-31 2013-12-31 A kind of nasal spray for the treatment of of allergic rhinitis Active CN103893174B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310749348.6A CN103893174B (en) 2013-12-31 2013-12-31 A kind of nasal spray for the treatment of of allergic rhinitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310749348.6A CN103893174B (en) 2013-12-31 2013-12-31 A kind of nasal spray for the treatment of of allergic rhinitis

Publications (2)

Publication Number Publication Date
CN103893174A CN103893174A (en) 2014-07-02
CN103893174B true CN103893174B (en) 2015-09-02

Family

ID=50984966

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310749348.6A Active CN103893174B (en) 2013-12-31 2013-12-31 A kind of nasal spray for the treatment of of allergic rhinitis

Country Status (1)

Country Link
CN (1) CN103893174B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103751189B (en) * 2014-01-01 2016-02-03 山东天顺药业股份有限公司 A kind of pharmaceutical composition for the treatment of rhinitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104498A (en) * 1993-04-01 1995-07-05 藤泽药品工业株式会社 A topical dosage form

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104498A (en) * 1993-04-01 1995-07-05 藤泽药品工业株式会社 A topical dosage form

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《色甘酸钠与氯化钠配伍的研究》;李大魁;《药学通报》;19810228;第19卷(第2期);第26-28页 *

Also Published As

Publication number Publication date
CN103893174A (en) 2014-07-02

Similar Documents

Publication Publication Date Title
CN103269687B (en) 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy compositions
CN102319209B (en) Nasal pharmaceutical formulations and methods of using the same
CN103260623B (en) 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy compositions
CN103751188B (en) A kind of that quick nasal spray of color Gan Naijia
US20170258861A1 (en) Treatment of Herpes, Pseudomonas, Staph, and Hepatitis
CN104274537A (en) Traditional Chinese medicine composition, and preparation method and application thereof
CN102961365A (en) Terbutaline sulfate oral instant film and preparation method thereof
CN103893174B (en) A kind of nasal spray for the treatment of of allergic rhinitis
CN107362141A (en) A kind of Anefrin Nasal Spray and preparation method thereof
CN101147735A (en) Pharmaceutical composition for injection and its medicine box
CN110302151A (en) Oral Dry Suspensions and preparation method thereof containing Oseltamivir phosphate
CN101874778A (en) Alpha-asarone spraying agent and preparation method thereof
CN103751189B (en) A kind of pharmaceutical composition for the treatment of rhinitis
CN102335132A (en) Asarin inhalation aerosol and preparation method thereof
CN102078325A (en) Nasal composition containing povidone iodine and cyclodextrin inclusion of glucocorticoid
RU2237475C1 (en) Combined preparation to remove symptoms of catarrhal diseases and grippe (variants)
CN103893131B (en) A kind of solid composite medicament containing Febustat
CN103520106A (en) Salbutamol sulphate inhalation aerosol and preparation method thereof
CN103732611B (en) The purposes of beta-adrenergic inverse agonist for giving up smoking
CN101940585B (en) Composite using orientin-2'-O-beta-L-galactoside as main component and application thereof
CN100453072C (en) Isatis root drops and preparation thereof
CN109528708A (en) Application of the Kaempferol in preparation treatment rhinitis drug
WO2022048180A1 (en) Use of polypeptide in drug for preventing and treating pneumonia
CN100358496C (en) 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof
CN117695224A (en) Nasal spray, preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Xu Yitie

Inventor after: Lin Hang

Inventor after: Yin Rui

Inventor after: Liang Xia

Inventor after: Li Benchao

Inventor after: Yang Jinling

Inventor before: Xu Yitie

Inventor before: Liang Xia

Inventor before: Li Benchao

Inventor before: Qin Qingfu

Inventor before: Dong Pingyuan

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: XU YITIE LIANG XIA LI BENCHAO QIN QINGFU DONG PINGYUAN TO: XU YITIE LIN HANG YIN RUI LIANG XIA LI BENCHAO YANG JINLING

C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20140702

Assignee: Shandong Tianshun Pharmaceutical Technology Co.,Ltd.

Assignor: SHANDONG TIANSHUN PHARMACEUTICAL Co.,Ltd.

Contract record no.: X2022980023693

Denomination of invention: A nasal spray for treating allergic rhinitis

Granted publication date: 20150902

License type: Common License

Record date: 20221201

EE01 Entry into force of recordation of patent licensing contract